Zheng Quan Zhi Xing·2025-03-28 09:37Core Viewpoint - Jiangsu Haoaobo Biopharmaceutical Co., Ltd. announced a change in the lead financial advisor for the ongoing acquisition by Shuangrun Zheng'an Information Consulting (Beijing) Co., Ltd. due to the departure of the previous advisor, Mr. Ma Ke [1][2] Group 1 - The company received a letter from China International Capital Corporation (CICC) regarding the change in the lead financial advisor for the acquisition project [1] - The previous lead financial advisor, Mr. Ma Ke, has left CICC due to personal work changes and can no longer fulfill his responsibilities [1] - The new lead financial advisors are Liu Shangquan, Xing Hongyuan, and Gao Mengxuan, and this change will not affect the quality or progress of the ongoing advisory work [2] Group 2 - The financial advisory team will continue to adhere to the requirements of the "Measures for the Administration of Listed Company Acquisitions" and other relevant laws and regulations [2] - The company assures that the continuity and effectiveness of the advisory work will be maintained despite the personnel change [2]